RxDoctor Payments Data

Himisha Beltran, MD

Medical Oncology · Boston, MANPI 1801950704

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $82,569 of the $106,381 with a category attached, or 77.6%. It is spread thinly across 16 manufacturers, the largest accounting for just 19.9%. 2025 is the largest year on record at $40,007, more than ten times the $2,198 reported in 2019.

$106,381in general payments, 2019–2025

Across 68 payments — averaging $1564.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Daiichi Sankyo Inc.$21K
  • Merck$21K
  • Bayer$17K
  • Astrazeneca UK Limited$13K
  • Pfizer$12K
  • Novartis$6K
  • plus $16K from 10 others
$344,017in research payments, 2019–2025

Across 13 payments — averaging $26,463 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Daiichi Sankyo Company LTD$284K
  • Blue Earth Diagnostics$55K
  • Novartis$4K
  • Novartis Pharma AG$609

What the payments were for

  • Consulting fees$82,56978%
  • Speaking & faculty fees$8,8108%
  • Travel & lodging$13,58713%
  • Food & beverage$1,4151%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$106,381 in reported general payments places this provider in the 85th percentile of 308 medical oncology providers in Massachusetts.

See all medical oncology providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$13,475
Medicare patients
61
Services billed
114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Boston

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →